Vodis Pharmaceuticals Inc. Announces addition of Paul Pelosi Jr. and Clive Boulton to the Board of Directors

September 15, 2014 - Vancouver, British Columbia – Vodis Pharmaceuticals Inc. (the “Company” or “Vodis”) (CSE: VP / FSE: 1JV)) is pleased to announce that Paul Pelosi Jr. and Clive Boulton have agreed to join the Board of Directors of Vodis.

Otto Folprecht, Chief Executive Officer and Director of Vodis, states: “We are extremely pleased that these gentlemen, with their extensive background and track record of accomplishment in government, business and law have decided to join the Board of Directors for Vodis.   Their combined public and private sector expertise will be an asset as the Company moves forward on its vision to be one of the leading companies in the marijuana sector in Canada and the United States of America.”

Mr. Paul Francis Pelosi, Jr. is a graduate of Georgetown University with a Bachelor of Arts in History (Cum Laude) and a JD/MBA (Joint Degree) with an emphasis on Human Rights and International Business. Mr. Pelosi has many experiences as a Director or Advisor to companies regarding strategic planning, sustainability and efficiency. Mr. Pelosi is a member of California State Bar, a California Real Estate Broker, and a Registered Securities Representative. Mr. Pelosi currently serves on the Board of Directors for LookSmart, Inc. and Targeted Medical. Mr. Pelosi has also worked with government organizations, including NASA and the City of San Francisco. Prior to independent consulting, Mr. Pelosi served many years with Bank of America Securities, Bank of America Countrywide and JP Morgan – Chase Manhattan where he worked in Corporate Finance, Institutional Sales, and the Residential Mortgage Industry.

Working with a combination of public and private organizations, Mr. Pelosi has focused on improving living conditions by foundation programs like the Cisco Connected Urban Development that developed policies and programs in recycling, toxics reduction, environmental justice, energy efficiency, and commute alternatives

Clive Boulton has been practising law since 1979, first at the Provincial Crown Counsel's office in Vancouver to gain trial experience after finishing his articles. For two years he did exclusively trial work in Provincial and Supreme Court and spent six months doing jury trials.

In 1981, Mr. Boulton entered private practice and has practiced in a variety of areas including fire losses, construction liability, commercial and vehicle fraud, real estate defence, medical malpractice defence and personal injury defence. He also handled personal injury plaintiff cases and continued to practice in the criminal courts.

Mr. Boulton is a trial lawyer and enjoys working with juries. He has appeared as counsel in the Supreme Court and the Court of Appeal of British Columbia.

As the Company is limited to having four Board members, Mr. Brian Gusko has graciously decided to resign in order to free up a position on the Board to facilitate the above appointments. He will continue in his role as Chief Financial Officer of Vodis.


Additionally, the Company has granted incentive stock options (the "Stock Options") pursuant to the Company’s stock option plan to management of the Company (the "Optionees") entitling the purchase of an aggregate of 550,000 common shares. 350,000 of those Stock Options are exercisable at a price of $0.45 until they expire on September 3, 2024. 200,000 of those Stock Options are exercisable at $0.58 until they expire on September 8, 2024


About Vodis Pharmaceuticals


Vodis is one of Canada’s foremost brand names in the medical marijuana business. Its products have consistently won or placed at each competition its growers have entered. The Company is waiting for a final inspection from Health Canada in order to become a Licenced Producer at its state-of-the-art 12,000 square foot facility in Canada.


Vodis is one of Canada’s foremost brand names in the medical marijuana business. Vodis’ growers have consistently won or placed at each competition they entered. The Company is well advanced in the MMPR application process to become a Licenced Producer at its state-of-the-art 12,000 square foot facility in Canada.


For further information please contact:


Brian Gusko

CFO & Director

Vodis Pharmaceuticals

104-1037 West Broadway

Vancouver, BC V6H 1E3

direct: 1-866-210-1420 ext. 106

web: www.vodis.ca


The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

Forward-Looking Information:


responsibility for the adequacy or accuracy hereof.

This news release contains forward-looking statements, which relate to future events or future performance and reflect management's current expectations and assumptions. Such forward-looking statements reflect management's current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected. All of the forward-looking statements made in this news release and any accompanying graphic links are qualified by these cautionary statements and those in our continuous disclosure filings available on SEDAR at www.sedar.com. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation. This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

Vodis Corporate

  • Page 1 of 75